Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS, INC. (REGN), sold 61,665 shares at $842.16 ($51.6M) on 2023-08-22, disclosed to the SEC on 2023-08-23.
Open-market sale of $51.6M REGN by EVP Research and Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $833.39 | 38,335 | $31.9M | 62.0% |
| 2 | $840.53 | 6,309 | $5.3M | 10.3% |
| 3 | $840.53 | 6,309 | $5.3M | 10.3% |
| 4 | $841.41 | 4,574 | $3.8M | 7.5% |
| 5 | $841.41 | 4,574 | $3.8M | 7.5% |
| 6 | $842.16 | 782 |
| $659K |
| 1.3% |
| 7 | $842.16 | 782 | $659K | 1.3% |
| Total | $836.26 avg | 61,665 | $51.6M | 100% |
| Filing → |
| REGN | SELL | 2022-08-08 | $28.4M | — | Filing → |
| REGN | SELL | 2021-05-18 | $18.2M | — | Filing → |
| REGN | SELL | 2020-05-11 | $5.9M | — | Filing → |